# Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation

> **NCT01436305** · PHASE2 · TERMINATED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 19 (actual)

## Conditions studied

- Kidney Transplantation
- Renal Transplantation

## Interventions

- **DRUG:** Alemtuzumab
- **DRUG:** MMF
- **BIOLOGICAL:** Basiliximab
- **DRUG:** Short-term Tac
- **DRUG:** tacrolimus
- **BIOLOGICAL:** Belatacept
- **DRUG:** methylprednisolone

## Key facts

- **NCT ID:** NCT01436305
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-09
- **Primary completion:** 2015-04
- **Final completion:** 2015-04
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** Secondary to safety concerns plus change in Campath® (alemtuzumab) availability.
- **Last updated:** 2017-09-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01436305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01436305, "Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01436305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*